Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials
Authors' conclusion
This exploratory study suggests the feasibility of predicting KOA endotypes using a minimal panel of tissue-turnover biomarkers.
Study context
- Population
- Knee osteoarthritis (KOA) participants from IMI-APPROACH (model development) and from the randomised placebo-controlled trials MIV-711, salmon calcitonin and UBX0101226 IMI-APPROACH
- Comparison
- Treatment effects across predicted biomarker-based endotypes (structural damage, inflammation, low tissue turnover) in prior KOA drug trials
Methodological detailsexploratory, hypothesis-generating biomarker endotyping study, multinomial logistic regression, post hoc analysis of randomised placebo-controlled trials
- Exploratory, hypothesis-generating biomarker endotyping study
- Multinomial logistic regression
- Post hoc analysis of randomised placebo-controlled trials
Primary result
As reported in the abstract
Treatment effect by predicted endotype
Structural damage endotype: 26-week reduction in NRS knee pain with MIV-711 (greatest numerical reduction), 95% CI −16.23%, 3.31%
−6.46%
Structural damage endotype (only endotype significant): 2-year reduction in WOMAC pain with salmon calcitonin, 95% CI −10.55%, −1.83%
−6.19%
Further findings
SD of 2-year change in WOMAC pain, top 20% probability of structural damage endotype, salmon calcitonin
- Reduction in SD of 2-year change in WOMAC pain
- 9-15%
- Potential reduction in needed sample size with enrichment
- 18-28%
Original publication
Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials. Arthritis Res Ther. Published 7 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →